Note: This study is currently only recruiting patients in the hospital.

If you are interested in being notified if this study begins recruiting from the general population, please use the 'I Am Interested' button below.

Deucravacitinib for the Treatment of Palmoplantar Pustulosis (PPP)

All participants will receive deucravacitinib 6 mg daily for 24 weeks, with in person study visits every 4 weeks.

Brigham and Women's Hospital Psoriasis Clinical Trials Skin Conditions
8 visits over 24 weeks
Estimated Time Commitment
Any Gender, 18-years or older
May Be Eligible
Payment up to $720
May Be Offered
Survey, Blood draw, Office visit, Medication
May Be Required
 
I Am Interested I Am Interested I Am Interested

This project is not recruiting.

Overview

What we are studying

Palmoplantar pustulosis (PPP) is a rare disease that can have a significant impact on an individual's physican functioning and quality of life.  It was previously considered a subtype of plaque psoriasis, but key differences have been discovered, suggesting it is a unique skin disease. There are currently few effective treatments for PPP because patients with PPP may not respond to treatments that are helpful for treating plaque psoriasis. 


 


 


Why it is important

There are currently no FDA-approved treatments for PPP. 


What we hope to accomplish

Deucravacitnib is a new oral medication FDA approved for plaque psoriasis. We are doing a study to learn if the medication will also be effective in treating palmoplantar pustulosis.

Principal Investigator

Megan Noe, MD

Brigham and Women's Hospital

Public Profile

Who can participate

We are looking for people who have palmoplantar pustulosis, diagnosised by a dermatologist, whose symptoms have not responded to previous treatments. Participants are not allow to use any other prescription treatments for palmoplantar pustulosis or other immunosuppressive medications while they are enrolled in the study. A questionnaire will need to be answered via phone to determine eligibility. In person visits every 4 weeks are required.

Who cannot participate

Participants with other immune-mediated conditions requiring immunosuppressive medicaitons, those with a history of cancer within the past 5 years, and women who are pregnant or breastfeeding are not eligible for participation


 

What you may be asked to do

All study participants will receive the study medicaiton for a total of 24 weeks. Participants will be evaluated in person with clinical questionnaires and clinical photographs every 4 weeks. Additionally, safety assessment of new symptoms/side effects will be asked at every visit and safety labs will be performed at prior to starting and at two points during the study.


Project activities may include:

  • Survey
  • Blood draw
  • Office visit
  • Medication

Estimated Time Commitment

8 visits over 24 weeks

What You May Get

We will pay you $720 dollars if you complete the study.  If you do not complete the study, we will pay you $90 dollars via check for each visit you complete.

Location

Brigham and Women's Hospital - Center for Clinical Investigation
221 Longwood Avenue, 3rd floor, Boston, MA 02115

Map it!


Travel

  • Accessible by public transportation
  • Parking available

Travel and Parking Details

Additional Information

ClinicalTrials.gov Identifier

NCT05710185


Study Phase

Phase 4: This project studies a drug or treatment that has already been approved by the FDA and studied in both healthy volunteers and participants with specific diseases or conditions. It will gather more information about long term safety and will help to understand how the drug or treatment can be most effective.


Participating Institutions


Funding Source

  • Industry
Top